FINWIRES · TerminalLIVE
FINWIRES

EU、新たな「アクセラレートEU」計画で化石燃料依存からの脱却を目指す

-- 欧州委員会は水曜日、不安定な化石燃料市場からEU市民を守りつつ、「クリーンで自国産のエネルギー」への移行を加速させるための包括的な戦略パッケージを発表した。 「アクセラレートEU」戦略では、在庫を監視し不足を防ぐための新たな燃料監視機関の設立を含む緊急対策に加え、エネルギーバウチャーや脆弱な世帯への税制優遇措置といった的を絞った財政支援策が概説されている。長期的なエネルギー自立に向けて、委員会は2026年夏までに電化行動計画を提示する予定で、産業、建築、運輸部門全体で石油とガスを再生可能エネルギーに置き換えることを目指す。 2030年まで年間6600億ユーロの投資が必要となるこの移行資金を確保するため、委員会は復興・強靭化ファシリティなどの既存の資金源と民間資金を活用する方針だ。 この提案は、中東紛争による原油価格の高騰を受け、EU首脳陣がエネルギー政策の見直しを求めたことに続くものだ。これらの措置は、木曜日から金曜日にかけてキプロスで開催される非公式欧州理事会で議論される見込みだ。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703